Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    BARDA Backs OraSure’s Immunoassay Diagnostic for Ebola

    By Global Biodefense StaffJune 15, 2015
    Ebola Virus POC Diagnostics
    Share
    Facebook LinkedIn Reddit Email

    The U.S. Department of Health and Human Services (HHS) has announced backing of a rapid antigen Ebola test with an award to OraSure Technologies, Inc. worth up to $10,364,225.

    The award was made via a Broad Agency Announcement for “Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures for BARDA”.

    To assist doctors in diagnosing Ebola virus disease quickly, OraSure Technologies will pursue further development of an Ebola virus diagnostic test for use in a doctor’s office, hospital, clinic, or field setting that will provide results within 20 minutes.

    “Fast and inexpensive point-of-care diagnostics will improve our ability to control Ebola virus disease outbreaks,” said Robin Robinson, Ph.D., director of ASPR’s Biomedical Advanced Research and Development Authority (BARDA), which will oversee this development program for HHS. “Faster diagnosis of Ebola virus infections allows for more immediate treatment and an earlier response to protect public health worldwide.”

    Diagnosing Ebola virus infections quickly in resource-poor areas would enable health care providers to isolate and provide necessary treatment and supportive care to patients suffering from Ebola. Quickly isolating patients helps limit the spread of the disease. Emerging evidence has shown that early initiation of supportive care improves outcomes for patients suffering from Ebola virus disease.

    The development of this simple, low-cost, lateral-flow test, called the OraQuick rapid Ebola antigen test, will take place under an initial $1.8 million contract with OraSure Technologies. Contract options may bring the value up to $10,364,225.

    In addition, OraSure will evaluate whether the test can be used in the post-mortem analysis of oral fluids. During the current epidemic, people died before Ebola virus infections could be confirmed, yet the bodies of people infected with Ebola virus would have remained highly infectious. A simple, rapid test that could determine disease status quickly from the body’s oral fluids would facilitate infection control efforts and support the appropriate handling of remains infected with the Ebola virus.

    The OraQuick rapid Ebola antigen test is the first point-of-care Ebola virus testing device to receive BARDA support. To help the United States prepare for and control Ebola virus disease outbreaks, BARDA also is supporting development of vaccines to prevent Ebola virus infections and therapeutic drugs to treat the disease.

    The contract was awarded under Solicitation Number: BAA-13-100-SOL-00013

    ASPR Awards BARDA Ebola Emerging Threats HHS POC Diagnostics
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleSanaria to Produce Malaria Vaccine for DoD
    Next Article Advancing Synthetic Chemistry: The DARPA ‘Make It’ Program

    Related Stories

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Biomarkers for Detection of Exposure to Nitrogen Mustards

    September 20, 2023

    The Basics on the Nipah Virus Outbreak in India

    September 19, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy